| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Klinik fur Neurologie, Klinikum der Johann-Wolfgang-Goethe-Universitaet, Frankfurt, Germany (Dr. H. Baas); Department of Neurology, Akershus Central Hospital, Nordbyhagen, Norway (Dr. A.G. Beiske); Department de Neurologie, CHUV, Laussane, Switzerland (Dr. J. Ghika); Department of Neurology, Radcliffe Infirmary, Oxford, UK (Dr. M. Jackson); Neurologische Klinik Klinikum der Philipps-Universitaet, Marburg, Germany (Dr. W.H. Oertel); Abteilung fur Neurologie, Virchow Klinikum, Berlin, Germany, and Universitaetsklinik fur Neurologie, Innsbruck, Austria (Drs. W. Poewe and G. Ransmayr).
Address correspondence to Prof Oertel, Neurologische Klinik, Zentrum fur Nervenheilkunde, Philipps Universitat Marburg, Rudolf-Bultmann Strasse 8, 35033 Marburg, Germany.
Abstract.
Background: More than 50% of patients with Parkinson's disease develop motor response fluctuations (the "wearing off" phenomenon) after more than five years of levodopa therapy. Inhibition of catechol-O-methyltransferase by tolcapone has been shown to increase levodopa bioavailability and plasma elimination half life, thereby prolonging the efficacy of levodopa.
Objectives: The primary objective was to evaluate the efficacy of tolcapone in reducing "wearing off" in levodopa treated, fluctuating parkinsonian patients. Secondary objectives included assessment of reduction in levodopa requirements, improvement in patients' clinical status, duration of improvements, and tolerability of tolcapone.
Methods: In this multicentre, randomised, double blind, placebo controlled trial, 58 patients received placebo, 60 received 100 mg tolcapone three times daily(tid), and 59 received 200 mg tolcapone tid, in addition to levodopa/benserazide.
Results: After three months with 200 mg tolcapone tid, "off" time decreased by 26.2% of the baseline value, "on" time increased by 20.6% (p < 0.01 vs. placebo), and the mean total daily levodopa dose decreased by 122 mg from the baseline dose of 676 mg (p < 0.01). These responses were maintained up to nine months. With 100 mg tolcapone tid, "off" time decreased by 31.5% (p < 0.05), "on" time increased by 21.3%(p < 0.01), and the mean total daily levodopa dose decreased by 109 mg from the baseline dose of 668 mg (p < 0.05). With 200 mg tolcapone tid, unified Parkinson's disease rating scale motor and total scores were significantly reduced, and quality of life (sickness impact profile) scores were significantly improved. Both dosages were well tolerated. Dyskinesia was the most often reported levodopa induced adverse event. Diarrhoea was the most often reported non-dopaminergic adverse event and the most frequent reason for withdrawal from the study: four patients in the 100 mg tolcapone tid group and six in the 200 mg tid group withdrew because of diarrhoea.
Conclusion: Tolcapone prolongs "on" time in fluctuating parkinsonian patients while allowing a reduction in daily levodopa dosage, thereby improving the efficacy of long term levodopa therapy.
Footnotes
Reprinted from Journal of Neurology, Neurosurgery, and Psychiatry 1997;63:421-428, with permission.
See Appendix for names of study investigators.
This study was supported by F Hoffmann-La Roche Ltd, Basel, Switzerland. It has been published as a condensed version in the Proceedings of the 4th International Congress of Movement Disorders, Berlin: Springer-Verlag, 1996
Received January 28, 1997 and in revised form June 23, 1997; accepted June 30, 1997.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
